Introduction
============

Gastric cancer is a major cause of cancer-related deaths worldwide, and it is the fifth most common malignancy [@B1]-[@B3]. Gastric cancer has a high incidence rate in East Asia, and in particular nearly 42% of global gastric cancer cases occur in China [@B4]. Despite advances in diagnosis and treatment, the prognosis for patients with advanced gastric cancer remains dismal.[@B5] Gastric carcinogenesis is a complex, multistep and sequential process [@B6]. Like other malignancies, many factors may contribute to the development of gastric cancer, such as nutrition, dietary habits, salt consumption, excessive alcohol intake, tobacco smoking, Helicobacter pylori (H.pylori) infection, chronic gastritis, atrophyintestinal metaplasia and dysplasia [@B7]-[@B12]. Besides these factors, a large number of studies have demonstrated that the development of gastric cancer is partly under genetic control [@B13]-[@B15]. Recently, several promising genes have been identified as potential gastric cancer susceptibility genes. An important one is the receptor for advanced glycation end products (*RAGE*) gene.

RAGE is an oncogenic multidisciplinary trans-membranous receptor expressed in a number of cells. As a member of immunoglobulin superfamily of receptors, RAGE carries unique properties that make it a key component in the pathogenesis of many diseases and their impediments, such as inflammation, vascular diseases and different malignancies [@B16]-[@B18]. In addition, numerous clinical studies confirmed that the expression of RAGE was associated with prostate cancer [@B19], gastric cancer [@B20], gallbladder cancer [@B21], pancreatic cancer [@B22], lung cancer [@B23], colorectal cancer [@B24] and oral squamous cell carcinoma [@B25]. Besides, growing evidence suggests that some single nucleotide polymorphisms (SNPs) in *RAGE* gene were related to the angiogenesis and tumor metastasis [@B25], and blocking RAGE signal can inhibit the growth and metastasis of glioma cells [@B26]. Gu et al. reported that mutation of *RAGE* gene rs2070600 was associated with a significantly higher risk of gastric cancer [@B15]. Based on above observations, it is reasonable to hypothesize that *RAGE* gene is a promising candidate of gastric cancer. To test this hypothesis, we here genotyped four well-characterized SNPs in *RAGE* gene, rs1800625 (T-429C), rs1800624 (T-374A), rs2070600 (Gly82Ser) and rs184003 (G1704T), to see whether their genetic variation can alter the risk of gastric cancer and associate with its invasion, metastasis and overall survival.

Materials and Methods
=====================

Ethics Statement
----------------

This study was approved by the Research Ethics Committee of Fujian Provincial Cancer Hospital.

Patients and Samples
--------------------

This study included 387 patients who had gastric cancer confirmed by histopathology at Fujian Provincial Cancer Hospital between January 2008 and December 2010, and all patients received no chemotherapy or radiotherapy. Of the total 387 patients recruited in this study, 18 patients were lost to follow-up, 369 patients with gastric cancer were assessed in final analysis. Another 493 cases of the same period who took physical examinations at this hospital were selected by a random number table method as control group, and they were matched with patients on age (± 5 years old), sex and place of residence. All study subjects were Han Chinese who lived in Fujian Province for more than 10 years, and had no blood relationship with each other. Tumor histological grade was determined according to the American Joint Committee on Cancer (AJCC) system (2010) and the International Union against Cancer (UICC). Written informed consents were obtained from all patients and controls.

Biospecimen and DNA Extraction
------------------------------

The adjacent tissues of gastric cancer specimens from patients were embedded in paraffin using standard methods. Then, genomic DNA was extracted according to the Tiagen DNA kit instructions. Controls provided 5 ml venous EDTA anticoagulant blood according to Beijing BioTeke of the whole blood extraction DNA kit operating instructions. The amount of DNA was detected by UV spectrophotometer, and absorbance values (A values), A260 and A280 were measured with the ratio ranging from 1.8 to 2.0.

SNP Selection and Genotyping
----------------------------

Four SNPs in *RAGE* gene, rs1800625 C\>T, rs1800624 T\>A, rs2070600 G\>A and rs184003 G\>T, that were widely evaluated with association diabetes and cancer were selected for analysis. SNP genotype information was retrieved from the dbSNP database (<http://www.ncbi.nlm.gov/projects/SNP/>). Genotyping was performed using the polymerase chain reaction - ligase detection reaction (PCR-LDR) method. The DNA fragment containing the SNP loci was amplified by PCR using an ABI9600 PCR instrument (Applied Biosystems, Foster City, CA, USA). The characteristics of sequences in this study are summarized in Table [1](#T1){ref-type="table"}.

PCR reaction was carried out in a total reaction volume of 15 μl, containing DNA 1 μl, 1.5 μl 10×buffer, 1.5 μl MgCL~2~, 0.3 μl DNTP (Fermentas, United States), 0.15 μl of each primer, 0.3 μl Taq enzyme (Fermentas, United States) and 10.25 μl H~2~O. The steps were as follows: initial denaturation step at 94℃ for 3 min, amplification was carried out by 35 cycles at 94℃ for 15 s, 54℃ for 15 s, and at 72℃ for 30 s, followed by a final elongation cycle at 72℃ for 3 min. The connection reaction was performed at adding the PCR product 3 μl, 1 U 10×Taq DNA ligase buffer (New England Biolabs, United States), 0.125 μl Taq DNA ligase (40 U/μl, New England Biolabs, United States ), probe (10p) 0.01 μl/strip and with H~2~O added to 10 μl under the condition of by cycles at 94℃ for 30 s, 56℃ for 3 min. LDR fluorescent products were analyzed by ABI 377 sequence analyzer (Perkin-Elmer, Foster City, CA, USA), and the results were analyzed by the fragment analysis software GeneMapper 3.7 (Applied Biosystems, Foster city, CA, USA).

To test the accuracy of PCR-LDR method, a total of 96 DNA samples were randomly selected from the total sample, and they were genotyped using the same method, with exactly the sample findings for duplicated samples.

Statistical Analysis
--------------------

Statistical analysis was performed using the SPSS software version 19.0 (SPSS Inc). Continuous variables were expressed as mean ± standard deviation (SD). Statistical significance was tested by a chi-square (χ^2^) or the Fisher\'s exact test. Satisfaction of all genotypes with the Hardy-Weinberg proportions was calculated in control groups. Linkage disequilibrium was depicted using the Haploview software version 4.2. The genotypes of four examined SNPs in *RAGE* gene were explored by unconditional logistic regression analyses to obtain odds ratio (OR) and its 95% confidence interval (CI). Survival curves were calculated according to the Kaplan-Meier method and compared using the log-rank test. A two-sided p-value \< 0.05 were considered statistically significant.

Results
=======

Clinical Characteristics
------------------------

The final analysis included 369 cases and 493 controls who were frequency matched as previously described. About 70.7% of gastric cancer patients were male, and patients aged 60 years or over accounted for 48.5%. 69.0% of controls were male, and controls aged 60 years or over accounted for 48.1% (Table [2](#T2){ref-type="table"}). There were no significant differences in age and sex between patients and controls (p\>0.05). The genotype distributions of four SNPs in controls were checked by the Hardy-Weinberg equilibrium test (Table [1](#T1){ref-type="table"}), and no deviations were noticed (all *p*\>0.05).

Association between RAGE Gene SNPs and Gastric Cancer Risk
----------------------------------------------------------

The linkage disequilibrium of four studied SNPs is presented in Supplementary Figure [1](#SM0){ref-type="supplementary-material"}. In logistic regression analyses, *RAGE* gene rs1800625 TT genotype was associated with a significantly reduced risk of gastric cancer (OR: 0.72; 95% CI 0.55-0.95; *p*=0.021) after adjusting for age and sex, and the power to reject the null hypothesis that this OR equals 1 was 66.1% (Table [3](#T3){ref-type="table"}). Additionally, the T allele also reduces the risk of gastric cancer (OR: 0.67; 95% CI 0.46-0.97; *p*=0.032), with study power of 82.4%. In contrast, there were no significant differences in the genotype and allele distributions of the other three polymorphisms between the cases and controls with the increase risk for the development of gastric cancer (all *p*\>0.05).

Association between RAGE Gene SNPs and Clinical Features
--------------------------------------------------------

Considering the association between SNPs and clinical features of patients with gastric cancer, we analyzed whether the variation of SNPs were linked to TNM stage and lymph node metastasis. In our study we found that the polymorphisms of *RAGE* gene rs1800625 and rs184003 were associated with tumor clinical stage (*p*=0.010, *p*=0.032, respectively) (Table [4](#T4){ref-type="table"}). However, no evidence demonstrated that the SNPs of *RAGE* gene was related to Lymph node metastasis of gastric cancer (all *p*\>0.05). As shown in Table [4](#T4){ref-type="table"}.

Association between RAGE Gene SNPs and Gastric Cancer Survival
--------------------------------------------------------------

In this study, we further analyzed whether the genotypes of studied SNPs had an association with gastric cancer survival. The Kaplan-Meier curves of survival in gastric cancer patients were shown in Figure [1](#F1){ref-type="fig"}. There was no significant difference in gender, age, height and weight between gastric cancer survivors and death patients (*p*\>0.05). A difference in survival curves was noted between rs1800625 genotypes. Patients who carried the T gene of rs1800625 had significantly longer survival time (*p*\<0.05, Figure [1](#F1){ref-type="fig"}A). However, no significantly association between the other three SNPs and gastric cancer survival time was observed.

Discussion
==========

The aim of this study was to test the hypothesis that *RAGE* gene was a promising candidate of gastric cancer. Our findings indicated that in *RAGE* gene, rs1800625 was associated with gastric cancer risk, and rs1800625 and rs184003 were related to tumor clinical stage, indicating that *RAGE* gene may be a gastric cancer-susceptibility gene.

It is well known that accumulating genetic variation plays crucial function roles within the tumorigenesis of gastric cancer [@B27]. In order to clarify potential biomarkers of gastric carcinogenesis, we selected four SNPs of *RAGE* gene and investigated their associations with the risk, metastasis and survival of gastric cancer in a population of Fujian, and our findings proposed that potentially functional SNPs of *RAGE* gene may play a role in the etiology of gastric cancer.

RAGE activates central cell pathways including mitogen-activated protein kinase, Cdc42 / Rac and nuclear factor-nB signaling by binding to ligands [@B17],[@B28],[@B29]. Previous studies demonstrated that the association between *RAGE* genetic polymorphisms and gastric cancer risk [@B15]. In this study, we found that *RAGE* gene rs1800625 TT genotype and T allele were significantly associated with a reduced risk of gastric cancer. In addition, accumulating evidence shows that the expression of *RAGE* gene may be strongly related to the invasive and metastatic activity of gastric cancer [@B19],[@B20]. Our findings indicated that two SNPs in *RAGE* gene, rs1800625 and rs184003, were associated with tumor clinical stage. Besides, the patients who carried the T gene of rs1800625 had significantly longer survival time.

Gu et al. found that this SNP was associated with the increased risk of gastric cancer among subgroups of younger subjects aged ≤ 58 years [@B15]. On the other hand, Li et al. reported that the rs2070600 AG genotype was significantly associated with an increased risk of gastric cancer among nonsmokers, nondrinkers and gastric cancer patients [@B1]. However, our results did not show similar results, and may need a large sample size and more detailed risk factor information to validate.

Several limitations for this study should be acknowledged. First, we only genotyped four well-defined SNPs in *RAGE* gene, and other SNPs were of additional interest in association with the risk and prognosis of gastric cancer. Second, the sample size involved was not large enough to derive a reliable estimate, and so our findings needed to be confirmed in large, well-designed studies. Third, only Chinese subjects were enrolled for analysis, and the extrapolation of our findings to the other ethnic groups was limited.

Taken together, our findings indicated that *RAGE* gene rs1800625 was associated with gastric cancer risk, and rs1800625 and rs184003 were related to tumor clinical stage, indicating that *RAGE* gene may be a gastric cancer-susceptibility gene.

Supplementary Material {#SM0}
======================
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Supplementary figure.
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Click here for additional data file.
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###### 

Primer sequences of RAGE gene four SNPs and the test of Hardy-Weinberg equilibrium

  SNPs        Upstream sequence               Downstream sequence              Case group\*   Control group\*
  ----------- ------------------------------- -------------------------------- -------------- -----------------
  rs1800625   5\'-AAACATGAGAAACCCCAGAA-3\'    5\'-TGTACCCTCTAGGGTCTCATTC-3\'   0.699^a^       0.277^b^
  rs1800624   5\'-AAACATGAGAAACCCCAGAA-3\'    5\'-TGTACCCTCTAGGGTCTCATTC-3\'   0.075          0.061
  rs2070600   5\'-CGTCACTCTGCCTCACAGTC-3\'    5\'-GTCTCCTTTCCATTCCTGTTC-3\'    0.251          0.729
  rs184003    5\'-AATTGGTGGTGGAGCCAGAAG-3\'   5\'-TTCAGATACCCTCTCTTCCTC-3\'    0.440          0.799

^\*^The *p* values of Hardy-Weinberg equilibrium test.

###### 

Demographic characteristics of the study subjects

  Characteristics         Total subjects (n=862)   Case group (n=369)   Control group (n=493)
  ----------------------- ------------------------ -------------------- -----------------------
  Age (years)                                                           
  ≥ 60                    416                      179 (48.5%)          237 (48.1%)
  \< 60                   446                      190 (51.5%)          256 (51.9%)
  Sex                                                                   
  Male                    601                      261 (70.7%)          340 (69.0%)
  Female                  261                      108 (29.3%)          153 (31.0%)
  TNM stage                                                             
  I                                                46                   
  II                                               72                   
  III                                              210                  
  IV                                               41                   
  Lymph node metastasis                                                 
  N0                                               88                   
  N1                                               86                   
  N2                                               81                   
  N3                                               114                  

###### 

Genotype distributions and allele frequencies of RAGE gene four SNPs between cases and controls

  SNPs           Controls (n=493)   Cases (n=369)   OR (95% CI)^a^      *p*
  -------------- ------------------ --------------- ------------------- -------
  rs1800625                                                             
  CC             6 (1.2%)           1 (0.3%)        1.00^ref^           
  CT             77 (15.6%)         44 (11.9%)      0.21 (0.03-1.76)    0.150
  TT             410 (83.2%)        324 (87.8%)     0.72 (0.55-0.95)    0.021
  C allele       89 (9%)            46 (6.2%)       1.00^ref^           
  T allele       897 (91%)          692 (93.8%)     0.67 (0.46-0.97)    0.032
  TT+CT vs. CC                                      4.53 (0.54-37.82)   0.249
  rs1800624                                                             
  TT             378 (76.7%)        274 (74.3%)     1.00^ref^           
  AT             102 (20.7%)        83 (22.5%)      0.79 (0.49-1.27)    0.323
  AA             13 (2.6%)          12 (3.3%)       0.88 (0.54-1.45)    0.619
  T allele       858 (87%)          631 (85.5%)     1.00^ref^           
  A allele       128 (13%)          107 (14.5%)     1.14 (0.86-1.50)    0.360
  AA+AT vs. TT                                      1.14 (0.83-1.56)    0.236
  rs2070600                                                             
  GG             325 (65.9%)        221 (59.9%)     1.00^ref^           
  GA             152 (30.8%)        134 (36.3%)     0.78 (0.50-1.22)    0.270
  AA             16 (3.2%)          14 (3.8%)       1.01 (0.65-1.57)    0.974
  G allele       802 (81.3%)        576 (78%)       1.00^ref^           
  A allele       184 (18.7%)        162 (22%)       1.22 (0.97-1.55)    0.092
  AA+AG vs. GG                                      1.30 (0.98-1.71)    0.074
  rs184003                                                              
  GG             318 (64.5%)        240 (65%)       1.00^ref^           
  GT             157 (31.8%)        118 (32%)       1.24 (0.78-1.97)    0.373
  TT             18 (3.7%)          11 (3%)         1.23 (0.77-1.96)    0.383
  G allele       793 (80.4%)        598 (81%)       1.00^ref^           
  T allele       193 (19.6%)        140 (19%)       1.04 (0.81-1.32)    0.75
  TT+GT vs. GG                                      0.98 (0.74-1.30)    0.886

*Abbreviations*: OR: odds ratio; CI: confidence interval.

^a^The *p* was calculated after adjusting for age and sex under logistic regression model.

###### 

Association between RAGE gene four SNPs and clinical characteristics of gastric cancer

  ------------------------------ --------------- -------- --------------- ----------- ----------- --------- -------- -------- --------- ----------- --------- ----------- ---------
  **Clinical characteristics**   **rs1800625**            **rs1800624**                                                                                                   
  **CC**                         **CT**          **TT**   ***p***         **CT+TT**   ***p***     **TT**    **AT**   **AA**   ***p***   **AT+AA**   ***p***               
  Lymph node metastasis                                                                                                                                                   
  N0                             0               9        79              0.532       88          0.303              69       16        3           0.562     19          0.329
  N1-N3                          1               32       231                         263                            192      64        8                     72          
  TNM stage                                                                                                                                                               
  I-II                           0               15       92              0.01        107         0.002              84       22        1           0.364     23          0.233
  III-IV                         1               26       215                         241                            175      57        10                    67          
                                 **rs2070600**            **rs184003**                                                                                                    
                                 **GG**          **GA**   **AA**          ***p***     **GA+AA**   ***p***            **GG**   **GT**    **TT**      ***p***   **GT+TT**   ***p***
  Lymph node metastasis                                                                                                                                                   
  N0                             54              30       4               0.984       34          0.95               56       28        4           0.73      32          0.86
  N1-N3                          158             97       9                           106                            173      84        7                     91          
  TNM stage                                                                                                                                                               
  I-II                           63              37       7               0.793       44          0.908              70       34        3           0.032     37          0.427
  III-IV                         147             89       6                           95                             159      76        7                     83          
  ------------------------------ --------------- -------- --------------- ----------- ----------- --------- -------- -------- --------- ----------- --------- ----------- ---------

*Abbreviations*: TNM, tumor node metastasis.

[^1]: \*Shared first authors.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
